NCT01878825View on ClinicalTrials.gov

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral™ (2013-2014 Season) in Adults Aged 18 Years and Older

PHASE3CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

July 18, 2013

Primary Completion Date

August 9, 2013

Study Completion Date

August 9, 2013

Conditions
Influenza
Interventions
BIOLOGICAL

Fluviral™

1 dose administered intramuscularly in deltoid region of non-dominant arm.

Trial Locations (1)

J1H 1Z1

GSK Investigational Site, Sherbrooke

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01878825 - Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral™ (2013-2014 Season) in Adults Aged 18 Years and Older | Biotech Hunter | Biotech Hunter